1. Median overall survival is longer for HER2-low breast cancer patients receiving trastuzumab deruxtecan compared with other chemotherapy treatment options. ...
1. Compared to trastuzumab emtansine, trastuzumab deruxtecan is associated with a lower risk of disease progression or death in patients ...
Click to read this study in JAMA Network Open.
1. Ribociclib plus letrozole provides significant overall survival benefit as compared to letrozole alone in patients with advanced breast cancer. ...
1. The incremental cost-effectiveness ratio of the pertuzumab group was $436,679 per QALY gained. 2. Even if pertuzumab were free, ...
1. Sacituzumab govitecan was shown to significantly increase overall survival in previously treated metastatic triple-negative breast cancer patients compared to ...
1. Heterogeneity in histological profile linked to improved overall survival, chemotherapy response, and clinical course despite triple-negative receptor status in ...
Click to read the study in The Lancet Oncology.
Click to read the study in European Journal of Cancer
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.